After Amgen (AMGN) announced topline data from its Phase 2 study of MariTide, the company’s subcutaneously administered GLP-1 weight loss drug, H.C. Wainwright contends that Viking Therapeutics’ (VKTX) VK2735 is outpacing Amgen’s MariTide with “faster and more effective” weight loss. While Viking’s study used weekly injections, and monthly dosing like Amgen’s may be more favorable, the firm believes this is not a disadvantage for VK2735, added the analyst, who argues that Viking’s safety and efficacy data position VK2735 “strongly in the competitive obesity treatment landscape.” The firm maintains a Buy rating and $102 price target on Viking shares.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VKTX:
- Positive Phase 2 Trial Results Drive Viking Therapeutics (VKTX) Stock Upwards
- Viking Therapeutics initiated with a Buy at B. Riley
- Viking Therapeutics reports results from Phase 2b clinical trial of VK2809
- Viking to present data from Phase 2b VOYAGE study in late breaker presentation
- Biotech Alert: Searches spiking for these stocks today
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
